论文部分内容阅读
目的探讨晚期糖基化终末产物受体(RAGE)及其配体钙粒蛋白A8(S100A8)和钙粒蛋白P(S100P)在良性前列腺增生(BPH)和前列腺癌组织中的表达及临床意义。方法应用免疫组化方法检测30例BPH组织和32例前列腺癌组织中RAGE及其配体S100A8和S100P的表达,并结合临床资料进行统计学分析。结果与BPH比较,前列腺癌组织RAGE及其配体S100A8和S100P的表达明显升高。RAGE的表达与前列腺癌患者术前前列腺特异性抗原(PSA)水平有关(P<0.05);RAGE及其配体S100A8和S100P的表达与前列腺癌的临床和肿瘤分期密切相关(P<0.05);RAGE分别与S100A8和S100P结合,在前列腺癌组织中的表达呈正相关(P<0.05)。结论 RAGE及其配体S100A8和S100P可能参与了前列腺癌的发生、发展、浸润和转移,三者有可能成为前列腺癌诊断和治疗的新靶点。
Objective To investigate the expression and clinical significance of RAGE and S100A8 and S100P in benign prostatic hyperplasia (BPH) and prostatic cancer . Methods The expressions of RAGE and its ligands S100A8 and S100P in 30 cases of BPH and 32 cases of prostate cancer were detected by immunohistochemistry. The clinical data were used for statistical analysis. Results Compared with BPH, the expressions of RAGE and its ligands S100A8 and S100P in prostate cancer tissues were significantly increased. The expression of RAGE was correlated with the level of preoperative prostate specific antigen (PSA) in patients with prostate cancer (P <0.05). The expression of RAGE and its ligands S100A8 and S100P was closely related to the clinical stage and tumor staging of prostate cancer (P <0.05). RAGE was positively correlated with S100A8 and S100P in prostate cancer (P <0.05). Conclusion RAGE and its ligands S100A8 and S100P may be involved in the occurrence, development, invasion and metastasis of prostate cancer, all of which may become a new target for the diagnosis and treatment of prostate cancer.